At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 244 enrolled
Drug / intervention
ASN002 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating ASN002 and Placebo Oral Tablet for Atopic Dermatitis. Completed, enrolled 244 participants across 47 sites in 3 countries.
Detailed Summary
This is a randomized double-blind/placebo study evaluate the efficacy of ASN002 in subjects with moderate to severe atopic dermatitis (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesCanada, Germany, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMay 2018
Enrollment StartJul 2018
Primary CompletionJul 2019
Study CompletionAug 2019
TodayJul 2026
First PostedMay 22, 2018
Enrollment StartJul 5, 2018
Primary CompletionJul 22, 2019
Study CompletionAug 14, 2019
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 8.1 years ago
Interventions
ASN002drug
Daily dose of ASN002 for 12 weeks
Placebo Oral Tabletdrug
Placebo of ASN002 for 12 weeks